
2/26/2010
Released: 2/24/2010 9:00 AM EST Newswise — A spray-on skin product and an injectable cell therapy for heart attack patients are among 17 regenerative medicine technologies that will be showcased during the Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.Representatives from 17 startup biotech companies have been selected to present their technologies to a group of venture capitalists and companies including DeNovo Ventures, Excel Venture Management, InterSouth Partners, Livingston Securities, Proteus Ventures, and Quaker BioVentures. The forum is an annual event to convene the regenerative medicine community to focus on fulfilling the promise of regenerative medicine, including best practices and business models. Keynote speakers and panelists will discuss scientific and clinical advances, trial design, venture funding and obtaining regulatory approval. The forum is open to executives from biotechnology, pharmaceutical, medical device, and regenerative medicine companies; patient advocacy groups and medical research foundations; institutional investors from private equity and venture capital firms; academic researchers, clinical researchers and physicians; and those interested in health care innovation and personalized medicine. "The entire focus of the forum is translating the science of regenerative medicine to patients in a timely and cost-effective manner," said Anthony Atala, M.D., director of the Wake Forest Institute for Regenerative Medicine, and a forum speaker. "The fact that so many promising technologies will be highlighted at the event attests to the promise of this field." Companies selected to present their technologies are: For more information about the event and to register, go to www.rmconferences.org About the Regenerative Medicine Foundation Launched in 2005, the Foundation hosted one of the first regulatory meetings with the U.S. Food and Drug Administration (FDA) on the topic of regenerative medicine, and was instrumental in the formation of STRAC, the Soldier Treatment and Regeneration Consortium, a precursor to the Armed Forces Institute of Regenerative Medicine (AFIRM), and the Washington, DC-based Alliance for Regenerative Medicine. Through educational programs, translational conferences and public policy initiatives, the Foundation advocates for increased medical research, promotes the training and education of scientists, and facilitates the translation of therapies to patients
Source: Wake Forest University Baptist Medical Center